Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Next Science Ltd ( (AU:NXS) ) is now available.
Next Science Ltd has issued 465,131 ordinary shares to its Managing Director and CEO, I.V. Hall, as part of the settlement for tranche 2 of the Sign-On Rights. This issuance was conducted without disclosure to investors under the Corporations Act, and the company confirms compliance with relevant legal provisions, indicating a transparent and regulated approach to executive compensation.
The most recent analyst rating on (AU:NXS) stock is a Buy with a A$0.40 price target. To see the full list of analyst forecasts on Next Science Ltd stock, see the AU:NXS Stock Forecast page.
More about Next Science Ltd
Next Science Ltd operates in the medical technology industry, focusing on innovative solutions for infection prevention and treatment. The company is known for its proprietary Xbio technology, which targets biofilm-based infections, a significant challenge in healthcare settings.
YTD Price Performance: 17.39%
Average Trading Volume: 427,599
Technical Sentiment Signal: Sell
Current Market Cap: A$39.44M
Find detailed analytics on NXS stock on TipRanks’ Stock Analysis page.